Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Biosimilar Efficacy Trials Can Be Waived under Certain Conditions: MHLW
Japan’s health ministry has clarified that comparative clinical efficacy trials for biosimilars can be omitted if sufficient data demonstrate biosimilarity to the reference biologic through pharmacokinetic (PK) or pharmacodynamic (PD) studies. The Ministry of Health, Labor and Welfare (MHLW) clarified…
To read the full story
Related Article
- PMDA Urges Quality-Driven Biosimilar Development as CES Waivers Take Hold
August 18, 2026
- CES Waivers Could Slow Biosimilar Uptake without Better Communication: Industry
July 23, 2026
- ICH Weighs Need for Biosimilar Efficacy Trials as Regulators Move Away from Routine Use
March 9, 2026
- English Versions of MHLW Biosimilar Trial Guidance, Q&As Now Available
March 13, 2024
- MHLW No Longer Requires Japanese Comparability Data for Certain Biosimilars: Q&A Update
January 26, 2024
- Biosimilar Guidelines Nearing 1st Revision in 10 Years, MHLW Taking Public Comments
July 2, 2019
REGULATORY
- MFN Now a Factor in Japan’s Drug Pricing Debate: New Pharma Policy Chief
September 11, 2026
- MHLW to Weigh Survey Data, Past Approach for FY2027 Revision: Official
September 10, 2026
- Chuikyo Reps Back Greater Transparency, but Lean toward Broader CEA Price Cuts
September 10, 2026
- OTC-Like Drug Charge Gets Prescription Field; No Double Charge with LLP Rule
September 10, 2026
- Defense Chief Seeks MHLW Help Securing Drugs for SDF
September 9, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…